The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbott Diabetes (I); Merrimack; Novartis
Stock and Other Ownership Interests - Jounce Therapeutics; Merrimack; Novartis
Patents, Royalties, Other Intellectual Property - Merrimack
CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).
 
Edward B. Garon
Consulting or Advisory Role - Dracen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Andrea Ardizzoni
Honoraria - Lilly; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst)
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech
 
Byoung Chul Cho
Stock and Other Ownership Interests - Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Pedro De Marchi
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Kyorin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche
Speakers' Bureau - AstraZeneca; Lilly; Roche; Sanofi
Research Funding - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche
 
Luis G. Paz-Ares
Leadership - European Medicines Agency (I); Genomica
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sysmex
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca Spain; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Evelo Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Oncology (Inst); Takeda (Inst); TRM Oncology (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Pfizer (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genzyme; Intuitive Surgical; Lilly; Merck; Pfizer; Purdue Pharma; Spectrum Pharmaceuticals; Sysmex
 
Michael Thomas
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; IQvia; IQvia; Lilly; Mediolanum Farmaceutici; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Bijoyesh Mookerjee
Employment - Novartis
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte; Novartis
 
Pilar Cazorla Arratia
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Jason Baum
No Relationships to Disclose
 
Yi-Yang Yvonne Lau
Employment - Novartis
 
Zewen Zhu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Yuhan
Travel, Accommodations, Expenses - Pfizer